Gland Pharma (GLAND) delivered in-line 2QFY22 results, led by a strong revenue growth across all geographies, despite increasing cost pressure on account of supply disruptions. With vaccine batch validation completed for Sputnik Lite and 2nd dose, GLAND awaits clarity on the lifting of export restrictions by the government. We lower our EPS estimate by 4%/2% for FY22/FY23, mainly to factor in some delay in commercialization of the Sputnik contract. We remain positive on GLAND based on its a) complex product filings including peptides, longacting injectables for regulated markets, b) commercialization of the Sputnik...